Affiliations 

  • 1 Zuraidah Yusoff, MSc. Universiti Putra Malaysia, Faculty of Medicine and Health Sciences, Department of Pathology, Immunology Unit, 43400 Serdang, Selangor, Malaysia.
  • 2 Maryam Maqbool, MSc. Universiti Putra Malaysia, Faculty of Medicine and Health Sciences, Genetic and Regenerative Medicine Research Centre, 43400 Serdang, Selangor, Malaysia.
  • 3 Elizabeth George, MD. Universiti Putra Malaysia, Faculty of Medicine and Health Sciences, Department of Pathology, Haematology Unit, 43400 UPM Serdang, Selangor, Malaysia.
  • 4 Roshida Hassan, MD. National Blood Centre, Kuala Lumpur, Malaysia.
  • 5 Rajesh Ramasamy, PhD. Universiti Putra Malaysia, Faculty of Medicine and Health Sciences, Department of Pathology, Immunology Unit, 43400 Serdang, Selangor, Malaysia. r.rajesh@medic.upm.edu.my
Med J Malaysia, 2016 Jun;71(3):105-10.
PMID: 27495882 MyJurnal

Abstract

Mesenchymal stem cells (MSCs) derived from human umbilical cord (UC) have been considered as an important tool for treating various malignancies, tissue repair and organ regeneration. Umbilical cord-derived mesenchymal stem cells (UC-MSCs) are better alternative to MSCs that derived from bone marrow (BM-MSCs) as they are regarded as medical waste with little ethical concern for research and easily culture-expanded. In this present study, the foetal distal end of human UC was utilised to generate MSC by explant method. Upon in vitro culture, adherent cells with fibroblastic morphology were generated with rapid growth kinetics. Under the respective inductive conditions, these cells were capable of differentiating into adipocytes and osteocytes; express an array of standard MSC's surface markers CD29, CD73, CD90, CD106 and MHC-class I. Further assessment of immunosuppression activity revealed that MSCs generated from UC had profoundly inhibited the proliferation of mitogen-activated T lymphocytes in a dosedependent manner. The current laboratory findings have reinforced the application of explant method to generate UCMSCs thus, exploring an ideal platform to fulfil the increasing demand of MSCs for research and potential clinical use.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.